ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

14 links0 made here, not in the record26 judgments2 judges (the rules as one: Rule based)2 record changes seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05319730A Study to EvaluateInvestigational Agents Withor Without Pembrolizumab(MK-3475) in ParticipantsWith Advanced EsophagealCancer Previously Exposedto Programmed Cell Death 1Merck Sharp & Dohme LLCPhase 1/Phase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 2 · ClinicalTrials.gov record · Version of 2026-10-02Oct 7 · ClinicalTrials.gov record · Version of 2026-10-07Version of 2026-10-07CONDITIONSEsophageal Squamous Cell Ca…The registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionEsophageal NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedParkinson Disease 4, Autoso…The registry's MeSH filing›Nov 14 · Rule based · MisfiledMisfiledDRUGSPaclitaxelIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · TestedComparatorIrinotecanIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · TestedComparatorPembrolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAnti-ILT4 Monoclonal Antibo…Entry “MK-4830”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedLenvatinibIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerSacituzumab tirumotecanIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAntihistaminesEntry “Antihistamine”, read by our na…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundINT013197Entry “H2 Receptor Antagonist”, read …›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundAcetaminophenEntry “Acetaminophen (or equivalent)”…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundDexamethasoneEntry “Dexamethasone (or equivalent)”…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundSteroidsEntry “Steroid Mouthwash (dexamethaso…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Paclitaxel

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Paclitaxel”the record gives no role
→judged→changed
How the 2 judgments split50%of judgments with a known value say Comparator
Comparator · 1
Tested · 1

All judgments on this study

WhenLinkJudgeDecisionState
Oct 2The record itselfClinicalTrials.gov recordVersion of 2026-10-02Record change
Oct 7The record itselfClinicalTrials.gov recordVersion of 2026-10-07Record change
Nov 2PaclitaxelClaude Opus 5.5ComparatorCurrent
Nov 2IrinotecanClaude Opus 5.5ComparatorCurrent
Nov 2PembrolizumabClaude Opus 5.5BackgroundCurrent
Nov 2Anti-ILT4 Monoclonal Antibody MK-4830Claude Opus 5.5TestedCurrent
Nov 2LenvatinibClaude Opus 5.5Background · partnerCurrent
Nov 2Sacituzumab tirumotecanClaude Opus 5.5TestedCurrent
Nov 2AntihistaminesClaude Opus 5.5BackgroundCurrent
Nov 2INT013197Claude Opus 5.5BackgroundCurrent
Nov 2AcetaminophenClaude Opus 5.5BackgroundCurrent
Nov 2DexamethasoneClaude Opus 5.5BackgroundCurrent
Nov 2SteroidsClaude Opus 5.5BackgroundCurrent
Nov 14Esophageal Squamous Cell CarcinomaRule based · condition-kind ruleFinest filed termCurrent
Nov 14Esophageal NeoplasmsRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Parkinson Disease 4, Autosomal Dominant Lewy BodyRule based · condition-kind ruleMisfiledCurrent
Nov 18PaclitaxelRule based · role ruleTestedOverridden
Nov 18IrinotecanRule based · role ruleTestedOverridden
Nov 18PembrolizumabRule based · role ruleBackgroundAgrees
Nov 18Anti-ILT4 Monoclonal Antibody MK-4830Rule based · role ruleBackgroundOverridden
Nov 18LenvatinibRule based · role ruleBackgroundAgrees
Nov 18Sacituzumab tirumotecanRule based · role ruleTestedAgrees
Nov 18AntihistaminesRule based · role ruleTestedOverridden
Nov 18INT013197Rule based · role ruleTestedOverridden
Nov 18AcetaminophenRule based · role ruleBackgroundAgrees
Nov 18DexamethasoneRule based · role ruleBackgroundAgrees
Nov 18SteroidsRule based · role ruleTestedOverridden
As of nowEsophageal Squamous Cell CarcinomaRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.